Detalhe da pesquisa
1.
Chitinases and chitinase-like proteins in asthma.
Semin Immunol
; 67: 101759, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031560
2.
RNA viruses alter house dust mite physiology and allergen production with no detected consequences for allergenicity.
Insect Mol Biol
; 32(2): 173-186, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36511188
3.
Granulocyte-colony stimulating factor: Missing link for stratification of type 2-high and type 2-low chronic rhinosinusitis patients.
J Allergy Clin Immunol
; 149(5): 1655-1665.e5, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35278495
4.
Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent.
Cytokine
; 157: 155934, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709568
5.
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.
Respir Res
; 23(1): 202, 2022 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945604
6.
COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies.
Allergy
; 77(1): 304-307, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34543444
7.
Protein citrullination and NET formation do not contribute to the pathology of A20/TNFAIP3 mutant mice.
Sci Rep
; 13(1): 17992, 2023 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865713
8.
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19.
Sci Transl Med
; 15(710): eadi0252, 2023 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611083
9.
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment.
Cell Rep Med
; 3(12): 100833, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459994
10.
TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C.
J Exp Med
; 219(2)2022 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914824
11.
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Lancet Respir Med
; 9(12): 1427-1438, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756178
12.
Correction to: Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 556, 2020 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32571394
13.
Correction to: Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 554, 2020 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-32571428
14.
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 468, 2020 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32493441
15.
Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 491, 2020 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503663
16.
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.
Front Immunol
; 11: 596761, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33329586
17.
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trial.
Trials
; 21(1): 934, 2020 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33213529